(Q38453261)

3 September 2017

1 reference

title

Sepsis: a roadmap for future research (English)

1 reference

3 September 2017

0 references

Jean-Louis Vincent

2

1 reference

3 September 2017

5

Derek C Angus

1 reference

3 September 2017

Thierry Calandra

6

1 reference

3 September 2017

Katia Jaton

7

1 reference

3 September 2017

8

Stefano Giulieri

1 reference

3 September 2017

11

1 reference

3 September 2017

12

Tom van der Poll

1 reference

3 September 2017

Jonathan Cohen

1

1 reference

3 September 2017

Neill K J Adhikari

3

1 reference

3 September 2017

Flavia R Machado

4

1 reference

3 September 2017

Julie Delaloye

9

1 reference

3 September 2017

Steven Opal

10

1 reference

3 September 2017

Eric Pelfrene

13

1 reference

3 September 2017

19 April 2015

1 reference

Lancet Infectious Diseases

3 September 2017

1 reference

3 September 2017

15

1 reference

3 September 2017

5

1 reference

3 September 2017

581-614

1 reference

Sepsis definitions: time for change

3 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Regulatory mandates for sepsis care--reasons for caution

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

1 reference

7 January 2021

Early goal-directed therapy in the treatment of severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

A randomized trial of protocol-based care for early septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Goal-directed resuscitation for patients with early septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Intensive versus conventional glucose control in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Reduced cortisol metabolism during critical illness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The search for effective therapy for sepsis: back to the drawing board?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The immunopathogenesis of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Genomic responses in mouse models poorly mimic human inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Sepsis: current dogma and new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The clinical research enterprise in critical care: what's right, what's wrong, and what's ahead?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Sepsis: time to reconsider the concept

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Role of selective V1a receptor agonism in ovine septic shock.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Developing a clinically feasible personalized medicine approach to pediatric septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

"Merinoff symposium 2010: sepsis"-speaking with one voice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The epidemiology of sepsis in the United States from 1979 through 2000

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Sepsis in European intensive care units: results of the SOAP study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Where do people die? An international comparison of the percentage of deaths occurring in hospital and residential aged care settings in 45 populations, using published and available statistics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Verbal autopsy: current practices and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Severe sepsis epidemiology: sampling, selection, and society

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

National estimates of severe sepsis in United States emergency departments.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Benchmarking the incidence and mortality of severe sepsis in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Assessment of incidence of severe sepsis in Sweden using different ways of abstracting International Classification of Diseases codes: difficulties with methods and interpretation of results

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Epidemiology of sepsis in Norway in 1999

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis*.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Hospital Deaths in Patients With Sepsis From 2 Independent Cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003-2009.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Comparison of trends in sepsis incidence and coding using administrative claims versus objective clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Trends in sepsis and infection sources in the United States. A population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Critical care and the global burden of critical illness in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Global burden of sepsis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Access to urban acute care services in high- vs. middle-income countries: an analysis of seven cities

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Time-critical mortality conditions in low-income and middle-income countries.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The epidemiology of sepsis in patients with malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Improved prognosis of septic shock in patients with cirrhosis: a multicenter study*.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Impact of HIV/AIDS on care and outcomes of severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Tobacco smoking increases the risk for death from pneumococcal pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Smoking and the outcome of infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Exercise training attenuates septic responses in conscious rats

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Endotoxin levels correlate positively with a sedentary lifestyle and negatively with highly trained subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Exercise training prevents skeletal muscle damage in an experimental sepsis model.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Regular and moderate exercise before experimental sepsis reduces the risk of lung and distal organ injury

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Inadequate exercise as a risk factor for sepsis mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Predictors of sepsis in moderately severely injured patients: an analysis of the National Trauma Data Bank

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The effects of estrogen on various organs: therapeutic approach for sepsis, trauma, and reperfusion injury. Part 1: central nervous system, lung, and heart

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The effects of estrogen on various organs: therapeutic approach for sepsis, trauma, and reperfusion injury. Part 2: liver, intestine, spleen, and kidney

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Gender differences in sepsis: cardiovascular and immunological aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Gender differences in cytokine secretion by human peripheral blood mononuclear cells: role of estrogen in modulating LPS-induced cytokine secretion in an ex vivo septic model.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Rac1 mediates sex difference in cardiac tumor necrosis factor-alpha expression via NADPH oxidase-ERK1/2/p38 MAPK pathway in endotoxemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Estradiol receptors agonists induced effects in rat intestinal microcirculation during sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Association between lymphotoxin-alpha (tumor necrosis factor-beta) intron polymorphism and predisposition to severe sepsis is modified by gender and age.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Association between CD14 promoter -159C/T polymorphism and the risk of sepsis and mortality: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Quantitative analysis of the association between interleukin-10 1082A/G polymorphism and susceptibility to sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Association between tumor necrosis factor-alpha promoter -308 A/G polymorphism and susceptibility to sepsis and sepsis mortality: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The toll-like receptor 4 Asp299Gly variant: no influence on LPS responsiveness or susceptibility to pulmonary tuberculosis in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Infection rate and acute organ dysfunction risk as explanations for racial differences in severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Do hospitals provide lower quality of care to black patients for pneumonia?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Common genetic variants account for differences in gene expression among ethnic groups

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Spread of an inactive form of caspase-12 in humans is due to recent positive selection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

International study of the prevalence and outcomes of infection in intensive care units

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

New method of classifying infections in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Association between source of infection and hospital mortality in patients who have septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Sixty years trying to define the malaria burden in Africa: have we made any progress?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Variation in critical care services across North America and Western Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Geographic access to high capability severe acute respiratory failure centers in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Intensive care unit capacity in low-income countries: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

National intensive care unit bed capacity and ICU patient characteristics in a low income country

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Critical care medicine in Nepal: where are we?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Ebola haemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Extended spectrum β-lactamase producers among nosocomial Enterobacteriaceae in Latin America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Availability of critical care resources to treat patients with severe sepsis or septic shock in Africa: a self-reported, continent-wide survey of anaesthesia providers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

International Nosocomial Infection Control Consortium (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Population burden of long-term survivorship after severe sepsis in older Americans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Disability among elderly survivors of mechanical ventilation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Does the hospital make you older faster?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Long-term cognitive impairment and functional disability among survivors of severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Quantitative aspects of septicemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Controlled clinical laboratory comparison of two supplemented aerobic and anaerobic media used in automated blood culture systems to detect bloodstream infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Direct identification of bacteria in positive blood culture bottles by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Matrix-assisted laser desorption ionization-time of flight mass spectrometry for direct bacterial identification from positive blood culture pellets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Rapid identification of bacteria in positive blood culture broths by matrix-assisted laser desorption ionization-time of flight mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Rapid identification of bacteria from positive blood culture bottles by use of matrix-assisted laser desorption-ionization time of flight mass spectrometry fingerprinting

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Real-time identification of bacteria and Candida species in positive blood culture broths by matrix-assisted laser desorption ionization-time of flight mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Rapid method for direct identification of bacteria in urine and blood culture samples by matrix-assisted laser desorption ionization time-of-flight mass spectrometry: intact cell vs. extraction method.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Identification of blood culture isolates directly from positive blood cultures by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry and a commercial extraction system: analysis of performance, cost, and turnaround t

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Impact of matrix-assisted laser desorption ionization time-of-flight mass spectrometry on the clinical management of patients with Gram-negative bacteremia: a prospective observational study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Matrix-assisted laser desorption ionization time-of-flight mass spectrometry and PCR-based rapid diagnosis of Staphylococcus aureus bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Reducing time to identification of positive blood cultures with MALDI-TOF MS analysis after a 5-h subculture

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Emerging technologies for the clinical microbiology laboratory.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

A simple blood-culture bacterial pellet preparation for faster accurate direct bacterial identification and antibiotic susceptibility testing with the VITEK 2 system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Evaluation of FilmArray and Verigene systems for rapid identification of positive blood cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Performance evaluation of the Verigene® (Nanosphere) and FilmArray® (BioFire®) molecular assays for identification of causative organisms in bacterial bloodstream infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Multiplex real-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

A multicenter trial to compare blood culture with polymerase chain reaction in severe human sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Potential clinical utility of polymerase chain reaction in microbiological testing for sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Evaluation of pathogen detection from clinical samples by real-time polymerase chain reaction using a sepsis pathogen DNA detection kit.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Multiplex PCR allows rapid and accurate diagnosis of bloodstream infections in newborns and children with suspected sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Biomarkers and molecular analysis to improve bloodstream infection diagnostics in an emergency care unit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Molecular diagnosis of bloodstream infections with a new dual-priming oligonucleotide-based multiplex PCR assay

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Rapid diagnosis of bloodstream infections with PCR followed by mass spectrometry.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Enhanced diagnostic yields of bacteremia and candidemia in blood specimens by PCR-electrospray ionization mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Improved sensitivity for molecular detection of bacterial and Candida infections in blood

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

1 reference

7 January 2021

Detection of microbial DNAemia: does it matter for sepsis management?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The diagnostic future for bloodstream infections?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Procalcitonin increase in early identification of critically ill patients at high risk of mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Postoperative plasma concentrations of procalcitonin after different types of surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Serum procalcitonin as a marker of post-cardiac arrest syndrome and long-term neurological recovery, but not of early-onset infections, in comatose post-anoxic patients treated with therapeutic hypothermia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Sepsis biomarkers: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

TREM-1 amplifies inflammation and is a crucial mediator of septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Combination biomarkers to diagnose sepsis in the critically ill patient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Serial determinations of neutrophil CD64 expression for the diagnosis and monitoring of sepsis in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Pancreatic stone protein is highly increased during posttraumatic sepsis and activates neutrophil granulocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

An integrated clinico-metabolomic model improves prediction of death in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The inflammatory response in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Strategies to improve drug development for sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Association between mitochondrial dysfunction and severity and outcome of septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Nonresolving inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The role of mitochondrial dysfunction in sepsis-induced multi-organ failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

How metabolism generates signals during innate immunity and inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Non-invasive assessment of barrier integrity and function of the human gut.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Inhibition of IKKβ in enterocytes exacerbates sepsis-induced intestinal injury and worsens mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Characteristic male urine microbiomes associate with asymptomatic sexually transmitted infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The female urinary microbiome: a comparison of women with and without urgency urinary incontinence.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Structure, function and diversity of the healthy human microbiome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The microbiome revolution

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

IL-22 ameliorates renal ischemia-reperfusion injury by targeting proximal tubule epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Insulin-like growth factor-1 levels contribute to the development of bacterial translocation in sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Intestinal Barrier Dysfunction in a Randomized Trial of a Specific Probiotic Composition in Acute Pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Phosphate-containing polyethylene glycol polymers prevent lethal sepsis by multidrug-resistant pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Endothelial injury in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Inflammation and coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Bench-to-bedside review: circulating microparticles--a new player in sepsis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Inflammation, endothelium, and coagulation in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Broken barriers: a new take on sepsis pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Matrix metalloproteases and PAR1 activation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Sepsis and Endothelial Permeability

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The harmful role of c5a on innate immunity in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

HMGB1 increases permeability of the endothelial cell monolayer via RAGE and Src family tyrosine kinase pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Peptide Bbeta(15-42) preserves endothelial barrier function in shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Selepressin, a new V1A receptor agonist: hemodynamic comparison to vasopressin in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The new normal: immunomodulatory agents against sepsis immune suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Immunotherapy for sepsis--a new approach against an ancient foe.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Reactivation of multiple viruses in patients with sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Temporal response of the human virome to immunosuppression and antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Is boosting the immune system in sepsis appropriate?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Secondary hemophagocytic lymphohistiocytosis and severe sepsis/ systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Strong Cytosine-Guanosine-Independent Immunostimulation in Humans and Other Primates by Synthetic Oligodeoxynucleotides with PyNTTTTGT Motifs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

SIRT1 inhibition during the hypoinflammatory phenotype of sepsis enhances immunity and improves outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Unlocking the potential of the human genome with RNA interference

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Bacteria activate sensory neurons that modulate pain and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

HMGB1 is a therapeutic target for sterile inflammation and infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Role of HMGB1 in apoptosis-mediated sepsis lethality

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

HMGB1 mediates cognitive impairment in sepsis survivors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The effect of sRAGE-Fc fusion protein attenuates inflammation and decreases mortality in a murine cecal ligation and puncture model.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Inhibition of Janus kinase 2 and signal transduction and activator of transcription 3 protect against cecal ligation and puncture-induced multiple organ damage and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Novel role of PKR in inflammasome activation and HMGB1 release

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

α7 nicotinic acetylcholine receptor signaling inhibits inflammasome activation by preventing mitochondrial DNA release

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Plasma ATP is required for neutrophil activation in a mouse sepsis model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Drug discovery: a jump-start for electroceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Bioelectronic medicines: a research roadmap

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Reflex principles of immunological homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Novel synthetic (poly)glycerolphosphate-based antistaphylococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Adjunctive treatment of severe sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Matched and mismatched metabolic fuels in lymphocyte function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Soluble TREM-like transcript-1 regulates leukocyte activation and controls microbial sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Inter-alpha inhibitor protein administration improves survival from neonatal sepsis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

PCSK9 is a critical regulator of the innate immune response and septic shock outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Pancreatic digestive enzyme blockade in the intestine increases survival after experimental shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit*

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Statins in endothelial signaling and activation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Proprotein convertases in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Improving clinical trials in the critically ill: unique challenge--sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Why have clinical trials in sepsis failed?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Improvement in Process of Care and Outcome After a Multicenter Severe Sepsis Educational Program in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Preclinical sepsis models

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

A network-based analysis of systemic inflammation in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

A genomic storm in critically injured humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Host-pathogen interactions in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The ACCP-SCCM consensus conference on sepsis and organ failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Alarmins: awaiting a clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Neutralization of tumor necrosis factor in preclinical models of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Adaptive trial design: could we use this approach to improve clinical trials in the field of global health?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

An adaptive, phase II, dose-finding clinical trial design to evaluate L-carnitine in the treatment of septic shock based on efficacy and predictive probability of subsequent phase III success

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Intensive insulin therapy and pentastarch resuscitation in severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Interplay between sepsis and chronic health

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Gatekeepers and Enablers: How Drug Regulators Respond to a Challenging and Changing Environment by Moving Toward a Proactive Attitude

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Sepsis studies need new direction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Clinical review: sepsis and septic shock--the potential of gene arrays

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Approaching clinical reality: markers for monitoring systemic inflammation and sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

An international sepsis survey: a study of doctors' knowledge and perception about sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Antibiotic resistance-the need for global solutions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

Quality of life after intensive care: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

The functional costs of ICU survivorship. Collaborating to improve post-ICU disability

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

IMPOSE (IMProving Outcomes after Sepsis)-the effect of a multidisciplinary follow-up service on health-related quality of life in patients postsepsis syndromes-a double-blinded randomised controlled trial: protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970112-X

7 January 2021

10.1016/S1473-3099(15)70112-X

Identifiers

DOI

1 reference

3 September 2017

1 reference